In this episode, discover the fight of Professor Asnafi and his team to improve the survival of young patients affected by T-ALL leukemia.
The speakers:
- Vahid Asnafi, researcher and director of the oncohematology laboratory at Necker Hospital – Sick Children in Paris
- Manon Delafoy, pediatrician and member of Professor Asnafi’s research team
The National Cancer Institute has supported Professor Asnafi’s work on T-ALL since 2015 through several calls for projects, for a total amount of €1,750,700.
Precision medicine: tailor-made for patients
Advances in research have provided a better understanding of the biological mechanisms underlying the development and progression of cancers. These very diverse mechanisms vary from one patient to another: each tumor is, in fact, different and has its own characteristics, whether at the level of the tumor cells themselves or their interaction with their environment.
Precision medicine, also called personalized medicine, therefore aims to offer the patient a treatment adapted to the characteristics of their tumor. It is currently based on two types of treatments: targeted therapies and specific immunotherapy.
Learn more about precision medicine.
Meeting the challenge of pediatric oncology
Each year in France, around 1,850 children and 450 adolescents are newly diagnosed with cancer. Certainly, the 5-year survival rate, often synonymous with recovery, now exceeds 80%, but we still need to do better and efforts must be stepped up. They must focus particularly in the field of research in order to advance knowledge of pediatric cancers, their causes and origins and promote the development of new treatments. The French government has made pediatric cancer research a priority in the fight against cancer.
Learn more about pediatric oncology.
Health
